Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. (Symbol: BEAT) is a cutting-edge medical technology company that focuses on developing and commercializing high-resolution ambulatory Electrocardiogram (ECG) solutions. These solutions are designed to detect and monitor cardiac diseases outside traditional healthcare settings, providing critical diagnostic capabilities in a more accessible manner.
HeartBeam's flagship product is an innovative, credit card-sized ECG device that is diagnostically equivalent to a cardiologist reading a patient's 12-lead ECG and examining the patient. This compact device integrates seamlessly with a cloud-based diagnostic expert system, offering a comprehensive and user-friendly solution for cardiac monitoring.
Notably, studies designed by Harvard Medical School faculty have demonstrated that HeartBeam's technology performs on par with, or better than, world-class cardiologists in diagnosing heart attacks. The system features personalized diagnostic thresholds and unique ECG markers that help pinpoint the location of a heart attack on a 3D heart model, enhancing the accuracy and depth of diagnostic information provided to healthcare professionals.
One of the key components of HeartBeam's technology is the iCardiologist application, which uses artificial intelligence and machine learning to continually improve its diagnostic accuracy and predictive capabilities. This application aids cardiologists by providing detailed patient analysis, thereby supporting more informed and timely medical decisions.
HeartBeam has developed a proprietary and patented Vector Electrocardiography (VECG) technology platform, which is the cornerstone of its high-resolution ECG solutions. The company has validated this platform and is in the process of seeking U.S. Food and Drug Administration (FDA) clearance for its initial telehealth products.
With its innovative approach and proven technology, HeartBeam is poised to make significant strides in the field of cardiac care, offering practical solutions that can be utilized outside traditional healthcare environments, thereby broadening access to critical diagnostic tools and improving patient outcomes.
Latest News: Source: HeartBeam, Inc.
- ------
- ------
- ------
HeartBeam, Inc. (NASDAQ: BEAT) will participate virtually in the H.C. Wainwright Global Investment Conference from
The company's CEO, Branislav Vajdic, CFO Rick Brounstein, and CBO Jon Hunt will conduct one-on-one meetings during the event. Jon Hunt will also deliver a virtual presentation available on-demand starting
This innovative digital healthcare company focuses on ECG telemedicine technology for heart attack detection, providing significant advancements in diagnosing cardiovascular diseases outside medical institutions.
HeartBeam, a digital healthcare company (NASDAQ: BEAT), reported its Q1 2022 results, highlighting a net loss of $2.1 million, up from $210,000 in Q1 2021. R&D expenses increased significantly to $734,000, compared to $29,000 in the prior year. The company remains on track for an FDA submission for its Emergency Department Myocardial Infarction software in Q2 2022 and a Telehealth solution in Q4 2022. With cash reserves of $11.2 million, HeartBeam anticipates a full commercial rollout of its ED Software Tool in Q1 2023.
The acquisition of RedCrow by Alira Health aims to enhance access to alternative investments in healthcare startups. Founded in 2016, RedCrow has raised $250 million through over 250 fundraises. This strategic move allows Alira to extend its patient engagement mission by involving them in the financing of new healthcare solutions. The financial terms of the acquisition remain undisclosed, but the collaboration is expected to democratize healthcare investing, promoting innovation in early-stage pharma and MedTech.
HeartBeam, Inc. (NASDAQ: BEAT) announces a conference call on May 12, 2022 at 4:30 p.m. Eastern time, to discuss its first-quarter results for the period ending March 31, 2022. The call will feature CEO Branislav Vajdic, CFO Richard Brounstein, and CBO Jon Hunt. Participants can join via telephone or webcast. A replay will be available until July 12, 2022. HeartBeam specializes in digital healthcare technology for heart attack detection using an innovative ECG device. For further details, visit www.heartbeam.com.
HeartBeam, Inc. (NASDAQ: BEAT) announced a virtual roadshow webinar scheduled for April 27, 2022, at 11:30 a.m. Eastern Time. The event will feature CEO Branislav Vajdic, CFO Richard Brounstein, and CBO Jon Hunt discussing recent company announcements and key milestones for 2022. Participants can join via a provided webcast link or dial-in numbers. A replay will be available for two months post-event. HeartBeam focuses on innovative ECG telemedicine technology aimed at enhancing heart attack detection for high-risk patients outside medical facilities.
HeartBeam, a digital healthcare company focused on ECG telemedicine for heart attack detection, announced significant progress for Q4 2021, including partnerships for its Emergency Department (ED) myocardial infarction software and telehealth solutions. Key highlights include a $14.9 million IPO, new partnerships with LIVMOR Inc. and Phoebe Putney Health System, and an experienced leadership team poised for commercialization. The company ended 2021 with $13.2 million in cash, projecting sufficient funds into 2023, aiming for FDA submissions in 2022 and 2023.
HeartBeam, Inc. (NASDAQ: BEAT) has entered a professional services agreement with Triple Ring Technologies for the development of a Telehealth 3D vector ECG collection device aimed at remote heart attack monitoring. This partnership will span five phases and is scheduled for FDA 510k submission in Q4 2022. The device is designed for patient use at home, providing crucial ECG data to physicians in real-time. With over 18 million people in the U.S. suffering from coronary artery disease, this innovative solution addresses a significant need in cardiac care.
HeartBeam, Inc. (NASDAQ: BEAT) will conduct a conference call on
HeartBeam, Inc. (NASDAQ: BEAT) has announced a Business Associate Agreement and Clinical Trial Agreement with Phoebe Putney Health System to conduct a pilot study of HeartBeam’s Myocardial Infarction software product. This partnership aims to evaluate the software’s effectiveness in detecting heart attacks in emergency settings. HeartBeam will conduct additional studies and pursue future scientific and commercial collaborations, enhancing its position in the telehealth space for remote heart attack detection.
HeartBeam, Inc. (NASDAQ: BEAT) has announced a partnership with LIVMOR Inc. to develop a HeartBeam branded version of LIVMOR's FDA-cleared Halo+ Remote Patient Monitoring (RPM) platform. This collaboration aims to enhance heart attack detection by customizing the platform for HeartBeam's products. CEO Branislav Vajdic emphasized that using LIVMOR's established platform will expedite the FDA submission of their heart attack detection software, aimed at Emergency Department settings, later this year. This partnership aims to improve the accuracy of myocardial infarction detection.
FAQ
What is the current stock price of Heartbeam (BEAT)?
What is the market cap of Heartbeam (BEAT)?
What does HeartBeam, Inc. do?
What is unique about HeartBeam's technology?
How does HeartBeam's iCardiologist application work?
What is VECG technology?
Has HeartBeam's technology been validated?
Is HeartBeam seeking FDA clearance?
What are the benefits of HeartBeam's ECG solutions?
Can HeartBeam's technology locate a heart attack?
How is HeartBeam improving cardiac care?
Where can I find the latest news on HeartBeam, Inc.?
